Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 3/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 16/20 | 0.43 |
| ▸ | RAMP1 | O60894 | 7/20 | 0.42 |
| ▸ | ADM2 | Q7Z4H4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658950 | 0.85 | CALCRL (0.48) | CALCACALCRLRAMP1 | |
| SCHEMBL29549672 | 0.85 | CALCRL (0.48) | CALCACALCRLRAMP1 | |
| SCHEMBL837966 | 0.85 | CALCA (0.46) | CALCACALCRLRAMP1ADM2 | |
| SCHEMBL845957 | 0.84 | CALCA (0.44) | CALCACALCRLRAMP1ADM2 | |
| SCHEMBL24962035 | 0.84 | CALCRL (0.44) | CALCACALCRLRAMP1 | |
| SCHEMBL1394658 | 0.83 | CALCA (0.63) | CALCACALCRL | |
| SCHEMBL10189878 | 0.83 | CALCA (0.63) | CALCACALCRL | |
| SCHEMBL1393888 | 0.83 | CALCA (0.63) | CALCACALCRL | |
| SCHEMBL877307 | 0.82 | CALCA (0.45) | CALCACALCRLRAMP1 | |
| SCHEMBL837386 | 0.81 | CALCRL (0.45) | CALCACALCRLRAMP1ADM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173655-B2 | Bicyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | CALCA 9/4885CALCRL 5/4885RAMP1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.